Recent studies showed that high expression of different AA transporters, such as SLC3A2 or SLC7A5, is related to poor outcomes in the luminal B ER+ breast cancer subtype (59), suggesting that this subtype might be particularly vulnerable to glutamine depletion. Here, SLC3A2 is linked to breast cancer.